Who is sponsoring NCT05727059?

NCT05727059 is sponsored by Magenta Medical Ltd..

What drugs are being tested in NCT05727059?

Interventions in NCT05727059: The Elevate™ System.

What condition does NCT05727059 study?

NCT05727059 studies High-risk Percutaneous Coronary Intervention.

Is NCT05727059 still recruiting?

NCT05727059 is currently completed. Last updated 26 September 2024.

Last reviewed 2024-09-26 · How we verify

NCT05727059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magenta Elevate™ EFS in High-Risk PCI Patients

Completed NA Last updated 26 September 2024

What this trial tests

NA trial testing The Elevate™ System in High-risk Percutaneous Coronary Intervention in 18 participants. Completed in 2 January 2024.

Timeline

8 May 2023

Primary endpoint
1 December 2023

2 January 2024

Quick facts

Lead sponsor	Magenta Medical Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	8 May 2023
Primary completion	1 December 2023
Estimated completion	2 January 2024
Sites	2 locations across United States

Drugs / interventions tested

The Elevate™ System

Conditions studied

High-risk Percutaneous Coronary Intervention — all drugs for High-risk Percutaneous Coronary Intervention →

Sponsor

Magenta Medical Ltd. — full company profile →

Who can join

Adults 18 to 84, any sex, with High-risk Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Elevate™ EFS study is designed to evaluate the safety and feasibility of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary interventions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of The Elevate™ System

Trials testing the same drug.

NCT06099548 — Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients · NA · active not recruiting

Other recruiting trials for High-risk Percutaneous Coronary Intervention

Currently open trials in the same condition.

NCT04477603 — Impella ECP Early Feasibility Study · NA · active not recruiting

Other Magenta Medical Ltd. trials

Trials by the same sponsor.

NCT07293923 — Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock · NA · recruiting
NCT07001332 — ELEVATE High-Risk PCI Pivotal Study · NA · recruiting
NCT06099548 — Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05727059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Magenta Medical Ltd.
Last refreshed: 26 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05727059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing